Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R beta

IL-2 R beta

Brief Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:Insulin-Dependent Diabetes Mellitus 10,Interleukin-2 Receptor alpha Subunit,TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,IL2R
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD2-H5221-Cell-based assay
 IL-2 R beta CELL

Human IL-2 R beta Protein, His Tag (Cat. No. CD2-H5221) inhibits the IL-15-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.38-0.45 µg/mL (Routinely tested).

ILB-C52H9-SPR
 IL-2 R beta SPR

Cynomolgus IL-2 R beta, His Tag (Cat. No. ILB-C52H9) immobilized on CM5 Chip can bind Cynomolgus IL-2, His Tag (Cat. No. IL2-C5249) with an affinity constant of 377 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

ILB-M5253-SPR
 IL-2 R beta SPR

Mouse IL-2, His Tag (Cat. No. IL2-M52H3) immobilized on CM5 Chip can bind Mouse IL-2 R beta, His Tag (Cat. No. ILA-M52H5) with an affinity constant of 17.6 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

IL2RB,RP5-1170K4.6,CD122,P70-75

Background

Interleukin-2 receptor (IL-2R) is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that binds and responds to a cytokine called IL-2. The IL-2R is made up of 3 subunits - α (CD25), β (CD122) and γ (CD132) - non-covalently associating. The α and β chains are involved in binding IL-2, while signal transduction following cytokine interaction is carried out by the γ-chain, along with the β subunit. CD122 is also known as IL2R beta, is a member of the type I cytokine receptor family. CD122 is the receptor for interleukin-2 and is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect United States Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Hodgkin Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Leukemia, Myelogenous, Chronic; Cytokine Release Syndrome Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Retinal Diseases; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Iritis; Thrombocytopenia; Uveitis; Rejection in heart transplantation; Lymphoma; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Juvenile; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; Myelodysplastic Syndromes; HTLV-I Infections; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Granulomatosis with Polyangiitis; Diabetes Mellitus, Type 1; Leukemia; HIV Infections Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect United States Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Hodgkin Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Leukemia, Myelogenous, Chronic; Cytokine Release Syndrome Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Retinal Diseases; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Iritis; Thrombocytopenia; Uveitis; Rejection in heart transplantation; Lymphoma; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Juvenile; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; Myelodysplastic Syndromes; HTLV-I Infections; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Granulomatosis with Polyangiitis; Diabetes Mellitus, Type 1; Leukemia; HIV Infections Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Skin Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Melanoma; Myelodysplastic-Myeloproliferative Diseases Details
RM-1995 RM-1995 Phase 1 Clinical Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Mesothelioma; Solid tumours; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Skin Melanoma; Biliary Tract Neoplasms Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
BA-1106 TS-1904; BA-1106; RR-102 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Solid tumours; Neoplasms Details
PT-101 PT-101; MK-6194 Phase 1 Clinical Pandion Therapeutics Colitis, Ulcerative; Dermatitis, Atopic Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Plc Graft vs Host Disease Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Inc Autoimmune Diseases Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Myeloid, Acute Details
Nemvaleukin alfa RDB-1450; RDB-1419; ALKS-4230 Phase 3 Clinical Alkermes Plc Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab A/S, Adc Therapeutics Sa Myelodysplastic Syndromes; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myeloproliferative Disorders; Solid tumours; Hodgkin Disease; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Skin Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Melanoma; Myelodysplastic-Myeloproliferative Diseases Details
RM-1995 RM-1995 Phase 1 Clinical Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Mesothelioma; Solid tumours; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Skin Melanoma; Biliary Tract Neoplasms Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
BA-1106 TS-1904; BA-1106; RR-102 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Solid tumours; Neoplasms Details
PT-101 PT-101; MK-6194 Phase 1 Clinical Pandion Therapeutics Colitis, Ulcerative; Dermatitis, Atopic Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Plc Graft vs Host Disease Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Inc Autoimmune Diseases Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Myeloid, Acute Details
Nemvaleukin alfa RDB-1450; RDB-1419; ALKS-4230 Phase 3 Clinical Alkermes Plc Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab A/S, Adc Therapeutics Sa Myelodysplastic Syndromes; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myeloproliferative Disorders; Solid tumours; Hodgkin Disease; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message